Published in Clin Cancer Res on October 01, 2000
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol (2011) 1.29
In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer (2006) 1.23
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2010) 1.22
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03
A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS One (2013) 0.95
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol (2004) 0.92
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol (2004) 0.91
Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J Cancer (2004) 0.90
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol (2009) 0.86
Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions. Sarcoma (2011) 0.83
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer (2009) 0.81
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res (2007) 0.81
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro Oncol (2013) 0.81
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res (2015) 0.79
NICE verdict on Temozolomide: where next? Br J Cancer (2002) 0.75
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature (1978) 9.21
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J (1986) 6.09
Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med (1989) 5.81
Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem (1978) 5.43
Polyamine metabolism and function. Am J Physiol (1982) 5.26
Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol (1979) 4.53
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med (1993) 4.28
Identification of an amplified, highly expressed gene in a human glioma. Science (1987) 4.21
Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol (1995) 3.53
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol (1995) 3.26
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
mTOR and cancer therapy. Oncogene (2006) 3.07
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
On the role of S-adenosyl-L-methionine in the biosynthesis of spermidine by rat prostate. J Biol Chem (1969) 2.97
Coding of border ownership in monkey visual cortex. J Neurosci (2000) 2.92
Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother (1979) 2.75
Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol (1980) 2.69
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol (1999) 2.69
Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol (1981) 2.65
Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc (1967) 2.44
Spermidine/spermine N1-acetyltransferase--the turning point in polyamine metabolism. FASEB J (1993) 2.44
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol (1998) 2.39
alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol (2006) 2.38
Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol (1966) 2.33
Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol (1998) 2.32
Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem (1981) 2.29
Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology (1995) 2.26
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
The resolution of active and inactive xanthine oxidase by affinity chromatography. J Biol Chem (1972) 2.22
Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother (1981) 2.21
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res (1983) 2.20
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med (2001) 2.20
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology (1980) 2.18
A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys (1972) 2.16
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A (1990) 2.14
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Human hypoxanthine phosphoribosyltransferase. I. Purification, properties, and specificity. J Biol Chem (1969) 2.01
The role of infrapopliteal MR angiography in patients undergoing optimal contrast angiography for chronic limb-threatening ischemia. J Vasc Interv Radiol (1998) 2.01
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Sociodemographic and psychosocial factors in childhood as predictors of adult mortality. Am J Public Health (1995) 1.98
EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 1.97
Predicting patient satisfaction from physicians' nonverbal communication skills. Med Care (1980) 1.95
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol (1995) 1.93
Biosynthesis of putrescine in the prostate gland of the rat. Biochem J (1968) 1.92
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol (1981) 1.92
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res (1997) 1.89
Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res (1988) 1.89
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res (1999) 1.89
In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother (1980) 1.87
Enzymatic release of 7-methylguanine from methylated DNA by rodent liver extracts. Proc Natl Acad Sci U S A (1981) 1.87
Formation and metabolism of alkylated nucleosides: possible role in carcinogenesis by nitroso compounds and alkylating agents. Adv Cancer Res (1977) 1.87
Proteins that bind to the yeast rDNA enhancer. J Biol Chem (1989) 1.86
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res (2000) 1.85
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem (1970) 1.84
Methylation of the O6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. Cancer Invest (1984) 1.83
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res (1993) 1.82
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst (1998) 1.82
Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol (1998) 1.79
Guanine phosphoribosyltransferase from Escherichia coli, specificity and properties. Biochemistry (1972) 1.77
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol (1998) 1.76
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Phosphate-stimulated breakdown of 5'-methylthioadenosine by rat ventral prostate. Biochem J (1969) 1.75
Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res (1994) 1.73
Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J (1997) 1.72
In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol Biochem Parasitol (1983) 1.69
Mechanism of action and selectivity of acyclovir. Am J Med (1982) 1.67
Concentrations of putrescine and polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem J (1970) 1.67
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J (2010) 1.66
Purification of ornithine decarboxylase from kidneys of androgen-treated mice. Biochemistry (1982) 1.65
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
A genetically tractable model of human glioma formation. Cancer Res (2001) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60